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Extensive research on antiviral small molecules starting
in the early 1970s has led to the identification of
10-carboxymethyl-9-acridanone (CMA) as a potent type I
interferon (IFN) inducer. Up to date, the mode of action of
this antiviral molecule has remained elusive. Here we
demonstrate that CMA mediates a cell-intrinsic type I IFN
response, depending on the ER-resident protein STING.
CMA directly binds to STING and triggers a strong anti-
viral response through the TBK1/IRF3 route. Interestingly,
while CMA displays extraordinary activity in phosphory-
lating IRF3 in the murine system, CMA fails to activate
human cells that are otherwise responsive to STING
ligands. This failure to activate human STING can be
ascribed to its inability to bind to the C-terminal ligand-
binding domain of human STING. Crystallographic studies
show that two CMA molecules bind to the central Cyclic
diguanylate (c-diGMP)-binding pocket of the STING dimer
and fold the lid region in a fashion similar, but partially
distinct, to c-diGMP. Altogether, these results provide
novel insight into ligand-sensing properties of STING
and, furthermore, unravel unexpected species-specific
differences of this innate sensor.
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Introduction
The innate immune system operates to sense microbial
infection. To this effect, it expresses a variety of so-called
pattern-recognition receptors (PRRs) that are able to sense
certain highly conserved microbial patterns, known as mi-
crobe-associated molecular patterns (MAMPs). Upon MAMP
sensing, cells of the innate immune system elicit certain
effector functions that are geared at eliminating the invading
pathogen. As such, cytokines play an important role in
orchestrating subsequent cellular immune responses or by
inducing antimicrobial effector functions in non-immune
cells. In this regard, cytokines of the type I interferon (IFN)
family play a pivotal role in eliciting antiviral, but also
antibacterial, effector functions. Soon after the discovery of
type I IFNs by Isaacs and Lindenmann (1957), many research
groups tried to delineate the mechanisms of its induction.
Early on, it was already noted that nucleic acid preparations
derived from viruses or enzymatic preparations were able to
trigger potent type I IFN responses. One of the most potent
triggers that emerged from these studies was the double-
stranded RNA polynucleotide mimic poly(I:C) (Isaacs et al,
1963; Rotem et al, 1963), but other polynucleotide
preparations, including double-stranded DNA (dsDNA),
were also reported to initiate antiviral immunity by eliciting
type I IFN responses. Moreover, in the early 1970s, several
groups tried to develop small-molecule compounds with
oral bioavailability that were able to trigger type I IFN
responses, thereby blocking viral replication. In the
course of these studies, the first small-molecule compound
reported was the tricyclic compound tilorone (2,7-bis(2-
diethylaminoethoxy)fluoren-9-one), which exhibited broad
antiviral activities against many viruses (Krueger and
Mayer, 1970; Mayer and Krueger, 1970). Subsequently,
additional heterocyclic compounds were reported to induce
type I IFNs, including various quinoline, anthraquinone
and acridine derivatives. Another structurally related
molecule that even surpassed most of these compounds in
antiviral activity was 10-carboxymethyl-9-acridanone (CMA),
discovered by Grunberg and colleagues, 1976. CMA was
shown to harbour potent antiviral activity and this could be
mainly ascribed to its ability to induce type I IFN production
(Taylor et al, 1980b; Kramer et al, 1981; Storch and Kirchner,
1982; Brehm et al, 1986; Storch et al, 1986).
However, while most of these small-molecule compounds
showed excellent type I IFN induction and antiviral activities
in rodents (Kramer et al, 1976; Taylor et al, 1980a,b), these
promising results failed to translate into the human system.
Tilorone, for example, showed no type I IFN induction in the
human system, both upon systemic or topic administration
(Kaufman et al, 1971), and at the same time, research
on CMA was abandoned by most groups. Nevertheless,
CMA is currently widely distributed and applied in Russia
for antiviral therapy, including hepatitis B virus, hepatitis C
virus, HIVor herpes simplex virus infection (Silin et al, 2009).
Three independent research approaches have led to the
discovery of STING as a protein that strongly induced type I
IFN production upon overexpression (Ishikawa and Barber,
2008; Zhong et al, 2008; Sun et al, 2009). Through its
N-terminal four-pass transmembrane region STING is
tethered to the ER, whereas its C-terminal region faces the
cytoplasmic lumen. STING-deficient cells show a profound
defect in sensing DNA viruses, and also synthetic DNA
ligands are strongly blunted in their capacity to induce
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pro-inflammatory gene expression in STING-deficient cells
(Ishikawa et al, 2009). At the same time, bacteria that
replicate in the cytoplasm, such as Listeria monocytogenes,
trigger type I IFN production in a STING-dependent manner
(Ishikawa et al, 2009). This finding was initially explained by
bacterial DNA being sensed in the cytoplasm in a STING-
dependent fashion. However, it turned out that type I IFN
production by L. monocytogenes could be mainly ascribed to
the cytoplasmic presence of the bacterial quorum-sensing
molecule cyclic diadenylate (c-diAMPs; Woodward
et al, 2010). Indeed, bacteria-derived c-diAMP or cyclic
diguanylate (c-diGMP) had already been described as
potent triggers of innate immune responses (Karaolis et al,
2007a,b; McWhirter et al, 2009). Both c-diAMP and c-diGMP
function as quorum-sensing molecules in bacteria, regulating
cell motility, biofilm formation and bacterial growth.
Surprisingly, STING turned out to be the direct sensor for
c-diGMP and c-diAMP, with its C-terminal part harbouring
the binding domain (Burdette et al, 2011). In addition, most
recently, it was discovered that cytosolic DNA sensing
triggers the formation of a novel second messenger, cyclic
GMP–AMP, which in turn binds to and activates STING (Sun
et al, 2013; Wu et al, 2013). This finding reconciles the
puzzling concept of STING serving as a sensor for
microbial cyclic dinucleotides and DNA at the same time.
Several groups have recently been able to solve the crystal
structure of c-diGMP binding to the C-terminal domain of
STING (Huang et al, 2012; Ouyang et al, 2012; Shang et al,
2012; Shu et al, 2012; Yin et al, 2012). These studies have
shown that the ligand-binding domain (LBD) of STING is
present as a preformed dimer that forms a V-shaped structure
harbouring a binding pocket for one c-diGMP molecule.
While ligand-binding does not induce a major confor-
mational change of the LBD of STING, a plausible model
of activation suggests that the C-terminal tail (CTT) of STING
is displaced from the pocket upon binding, so that it can
interact with TBK1 (Yin et al, 2012). TBK1 subsequently leads
to the phosphorylation of IRF3 and thereby induces
transcription of antiviral genes.
In this study, we elucidate the molecular mechanism of
CMA, a long-known small-molecule inducer of antiviral
responses. In the murine system, CMA was found to be a
potent activator of type I IFN production, yet in the human
system it failed to elicit detectable antiviral responses. CMA
activity depends on STING, and non-responsive human cells
can be conferred responsive by overexpressing murine
STING or a chimeric version of human STING that contains
the LBD of murine STING. Differential scanning fluorimetry
(DSF) studies using the LBDs of murine and human
STING furthermore indicate that unresponsiveness of
human STING to CMA is due to a lack of ligand binding.
The crystal structure of CMA bound to murine STING shows
that two CMA molecules bind the central c-diGMP-binding
cavity in a fashion representing the inherent c-diGMP
molecule symmetry, whereas differences are found in the
folding of the lid region. While the structural studies
cannot explain the species specificity in CMA detection, we
provide additional data that suggest a differential involve-
ment of the STING ‘lid region’ in CMA versus c-diGMP
recognition. Altogether, these data reveal important insight
into the species-specific recognition of a novel class of STING
ligands.
Results
CMA is a potent trigger of the type I IFN response
in murine macrophages
Intrigued by earlier publications on the antiviral activity of
CMA (Figure 1A), we were interested in the molecular
mechanisms of its activation, especially its putative receptor
and associated signalling routes. We first assessed its ability
to induce type I IFN production in macrophages in compar-
ison to defined ligands for various PRR systems. To this
effect, LPS (TLR4), transfected poly(I:C) (TLR3 and MDA5),
transfected 50triphosphate RNA (pppRNA/RIG-I) and trans-
fected 45mer dsDNA (ISD/STING) were used. All ligands
were tested at their previously determined optimal concen-
trations, and as readouts we assessed phosphorylation of
IRF3, transcription of Ifnb mRNA, IFNb protein levels
and transactivation of the IFNb promoter, using pIFNb-Luc
reporter mouse macrophages (Lienenklaus et al, 2009).
Indeed, CMA induced robust IRF3 phosphorylation that was
followed by strong Ifnb mRNA induction and translation
(Figure 1B–E). CMA-mediated IFNb production reached
peak levels already 4 h after stimulation, even exceeding
LPS in its readiness to trigger IFNb synthesis (Figure 1F).
Of note, for the various ligands studied, IRF3 phosphoryla-
tion, Ifnb mRNA induction and its translation did not go in
parallel, which is attributable to the fact that additional
ligand properties can play important roles in regulating
transcription and translation of this key cytokine. Assessing
other IRF3-dependent targets, such as IP-10, corroborated the
notion of CMA being a potent trigger of antiviral immunity,
yet NF-kB target cytokines (e.g., IL-6) were induced to a
lesser degree in CMA-stimulated cells (Figure 1G,H). In line
with this observation, assessing IRF3, MAPK and NF-kB
activation following CMA stimulation showed that CMA led
to synchronous and rapid activation of all these signalling
cascades, with a predominant IRF3 signature. LPS, on the
other hand, showed stronger NF-kB and MAPK activation,
with a slight delay in IRF3 phosphorylation (Figure 1I). At the
functional level, CMA blocked viral gene expression of
VSV-based replicon particles in a dose-dependent manner
(Supplementary Figure S1; Berger Rentsch and Zimmer,
2011). Altogether, these studies indicated that CMA is a
rapid and potent inducer of antiviral immune responses in
murine macrophages.
CMA-dependent type I IFN production requires STING
While most immortalized cell lines did not respond to CMA
(e.g., immortalized murine embryonic fibroblasts (MEFs),
HEK 293T cells, HeLa cells), early-passage MEFs could
be stimulated with CMA. This allowed us to use MEFs
from TBK1/IKKe-deficient mice, to determine the role of
these canonical kinases in IRF3 phosphorylation. As
expected, IRF3 phosphorylation was completed blunted in
MEFs deficient for TBK1 and IKKe (Supplementary Figure
S2A). We next assessed the role of TLR signalling pathways
using macrophages from mice deficient in MyD88 or TRIF.
Neither MyD88 nor TRIF were required for CMA sensing,
which ruled out an involvement of TLRs (Supplementary
Figure S2B–D). At the same time, absence of MAVS, the
shared signalling adapter of RIG-I and MDA5, had no impact
on CMA-mediated antiviral immunity (Supplementary
Figure S2E,F). We next went on to study the role of STING
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in CMA-triggered type I IFN production. To this effect, we
used macrophages from a mutant mouse strain, Goldenticket,
that harbours a missense mutation (I199N) in STING
(Sauer et al, 2011). Indeed, macrophages from these mice
showed no detectable activation of IRF3 or NF-kB (Figure 2A)
and also a complete absence of cytokine production
(Figure 2B). In addition, the antiviral activity elicited by
CMA treatment was completely abolished when STING-
deficient macrophages were stimulated (Supplementary
Figure S3). In line with the critical requirement of STING in
CMA sensing, a human HEK 293T cell line engineered to
stably express murine STING responded to CMA, with a
strong increase in pIFNb or pELAM reporter activity
(Supplementary Figure S4). As expected, this cell line also
showed a strong gain-of-function signal with regards to
c-diGMP sensing, which is usually non-functional in unmo-
dified HEK 293T cells. Altogether, these results indicated that
STING was required and also sufficient for CMA recognition.
CMA fails to activate human STING
Despite the fact that CMA had been reported to induce type I
IFN responses in human cells (Silin et al, 2009), we were
unable to elicit type I IFN production in various cell types of
the human system. Human PBMCs readily responded to
50pppRNA, poly(I:C), DNA, c-diGMP and LPS stimulation,
yet CMA failed to induce detectable cytokine responses, even
at high doses (Figure 3A–C). A similar picture was seen when
primary human fibroblasts were used (Figure 3 D,E).
In line with this finding, when we transiently transfected
HEK 293T cells with a human STING construct, no CMA
response could be detected, despite the fact that overexpres-
sion of human STING rendered 293T cells sensitive to
c-diGMP (Figure 4A). At the same time, transient overexpres-
sion of murine STING made HEK 293T cells responsive
towards both c-diGMP and CMA (Figure 4B). The fact that
human STING displayed c-diGMP-dependent signalling
capacity in HEK 293T cells suggested that the C-terminal
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Figure 1 CMA strongly induces type I IFN in primary mouse macrophages. (A) The chemical structure of CMA is depicted. (B–E and G–H)
Bone marrow-derived macrophages were transfected with poly(I:C), pppRNA and ISD, or stimulated with LPS or CMA (500mg/ml). (B) After
2 h, cells were collected and subjected to SDS–PAGE, and western blotting for phospho-IRF3 (P-IRF3) was performed. (C) Four hours after
stimulation, transcription of the IFNb gene (Ifnb) was assessed by quantitative RT–PCR, with normalization to HPRT1. (D) Eighteen hours
after stimulation, IFNb was measured in the supernatants by enzyme-linked immunosorbent assay (ELISA). (E) pIFNb-firefly-luciferase
(pIFNb-FFLuc) macrophages were stimulated as indicated. After 18 h, cells were lysed with passive lysis buffer, and FFLuc activity was
measured in the lysates. (F) pIFNb-FFLuc macrophages were stimulated with LPS or CMA (500mg/ml). Luciferase activity was assessed at the
indicated time points (in hours). (G,H) Eighteen hours after stimulation, IP-10 (G) and IL-6 (H) were measured in the supernatants by ELISA.
(I) Bone marrow-derived macrophages were stimulated with LPS or CMA (500mg/ml). Total protein was collected at indicated time points
(in minutes) after stimulation and was assessed for P-IRF3, phospho-NF-kB-p65 (P-NF-kB p65), IkBa, phospho-p38 (P-p38) or phospho-SAPK/
JNK (P-SAPK/JNK). Representative results out of three independent experiments are depicted. Source data for this figure is available on the
online supplementary information page.
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LBD of STING could be held responsible for the insen-
sitivity towards CMA. To address this question, we
constructed chimeric STING constructs, in which the
N- and C-terminal domains of the murine or human STING
were exchanged: mmSTING(1-137)-hSTING(139-379) or
hSTING(1-138)-mmSTING(138-378) (Figure 4C,D). Testing
these constructs in HEK 293T cells revealed that as long as
the murine LBD was present (hSTING(1-138)-mmSTING
(138-378); Figure 4D), CMA was able to trigger type I IFN
production. Altogether, these results indicated that unrespon-
siveness of human cells towards CMA could be explained
by species-dependent differences in the LBD of STING.
Using the murine STING construct, we next wanted to
address the role of functionally relevant point mutations for
the recognition of CMA. The previously described null-
mutant I199N most likely perturbs the structure of STING
and thereby abolishes c-diGMP binding and signalling
(Burdette et al, 2011). In line with this notion,
overexpression of mmSTING-I199N showed no pIFNb-Luc
transactivation upon CMA- or c-diGMP-mediated stimulation
(Supplementary Figure S5A,B). Interestingly, mmSTING-
R231A, a mutant that has previously been described to
completely blunt c-diGMP-mediated STING activation despite
binding, showed normal activity upon CMA stimulation
(Supplementary Figure S5C). These data demonstrated that
c-diGMP sensing could be dissociated from CMA recognition
at the receptor level.
CMA does not bind the human STING LBD
The failure of CMA to activate human STING could be
explained by several scenarios. Foremost, we wanted
to rule out the possibility that human STING does not bind
to CMA. To address this question, we expressed and purified
the LBD of murine and human STING in E. coli and tested its
ability to associate with various ligands, using DSF. DSF
indirectly assesses the association of a low molecular weight
compound to a purified protein by measuring the stability of
a protein–compound complex as a function of temperature
(Niesen et al, 2007). As indicated by a robust thermal shift,
the LBD of murine STING associated with its known ligands
c-diGMP and c-diAMP, and also binding to CMA, could
be observed (Figure 5A). At the same time, also the LBD of
human STING displayed association with c-diGMP and
c-diAMP, as indicated by a dose-dependent shift in thermal
stability. However, addition of CMA had no detectable impact
on the thermal stability of human STING, indicating that
CMA does not bind human STING (Figure 5B). Despite high
homology, murine and human STING show least conserva-
tion in their CTT region. As such, we additionally wanted to
rule out that this part of STING was required for CMA
binding. To this effect, we generated truncated versions of
the murine STING LBD lacking the CTT. However, testing this
variant showed similar binding properties as the full-length
LBD, indicating that the CTT is not required for ligand
binding by STING (Supplementary Figure S6).
The crystal structure shows a c-diGMP-like STING
interaction for CMA
Recently, five independent groups determined the crystal
structure of the LBD of human STING bound to c-diGMP
(Huang et al, 2012; Ouyang et al, 2012; Shang et al, 2012; Shu
et al, 2012; Yin et al, 2012). In these studies it was shown that
the LBD of STING constitutes a preformed dimer that is
stabilized through homotypic interaction at a hydrophobic
interface. This STING dimer forms a V-shaped pocket, in
which one c-diGMP molecule is buried at its bottom. To see
how CMA binds murine STING, we crystallized murine
STING LBD in the presence of CMA and determined the
crystal structure to 2.75 A˚ resolution (Supplementary Table
S1). The final model comprises two STING LBDs along with
two well-resolved CMA molecules (Figure 6A,B). Murine
STING LBD forms a dimer with high overall structural
similarity to the previously determined human STING LBDs
(Supplementary Figure S7). Two CMA molecules are located
in the deep central c-diGMP-binding pocket at the dimer
interface. The acridone ring moieties of both CMAs partially
stack to each other (B4 A˚ distance) in a parallel, laterally
shifted orientation, resembling the twofold symmetry
of c-diGMP. They are situated near the phosphate–ribose
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and STING-deficient macrophages were stimulated with LPS and
CMA (500mg/ml). Phospho-IRF3 (P-IRF3) and phospho-NF-kB-p65
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assay. Representative results out of two independent experiments
are depicted, whereas data are presented as mean valuesþ s.e.m.
Source data for this figure is available on the online supplementary
information page.
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binding site for c-diGMP, but due to the flat shape can wedge
deep into the helical bundle core of the LBD dimer. As a
result, CMA binds directly to Thr226 at the bottom of the
ligand-binding pocket, whereas c-diGMP binds via a water
molecule (Figure 6C,D).
Significantly, we find two well-ordered lid domains in a
four-stranded antiparallel b-sheet that closes the CMA/
c-diGMP-binding pocket (Figure 6A,B). The lids are generally
in a similar conformation than the folded lids in the human
STING–c-diGMP complex reported by Huang et al (2012)
(PDB-code: 4F5D), but there are also differences. The
carboxymethyl groups of the CMA moieties face and
stabilize the conformation of the lid by forming salt bridges
to both Arg237 residues. The equivalent human Arg238
residues stack between the two c-diGMP guanine moieties,
thereby stabilizing the lid. The space of the guanine moieties
is unoccupied by CMA. As a result, murine Arg237 and
Tyr167, plus Tyr240, directly stack instead of sandwiching
guanine as observed in the human c-diGMP complex. The
direct stacking induces or enables further closure of the
V-shaped binding cleft compared to the c-diGMP-bound
conformation, which may contribute to active signalling.
However, the tips of the lids fold differently in the presence
of CMA and c-diGMP. In particular, Arg231 (human Arg232),
which binds the phosphates of c-diGMP via a magnesium ion
or water molecule (Huang et al, 2012), is pushed to the
surface due to steric hindrance from the acridone ring. In
summary, CMA binds to the c-diGMP-binding pocket, with
two stacked CMA molecules mimicking the symmetric
c-diGMP. CMA induces a conformation in the LBD dimer
that is similar, if not more pronounced than the proposed
signalling conformation of human LBD, with folded lids in
the presence of c-diGMP, but also results in a somewhat
altered lid conformation. Altogether, the structure can explain
why CMA activates murine STING.
Discussion
In line with early reports on the antiviral activity of CMA
(Storch and Kirchner, 1982; Storch et al, 1986), our data
confirm the extraordinary type I IFN-inducing capacity of
CMA in the murine system. Further analysis of signalling
cascades involved in IFNb transactivation show a quick and
strong phosphorylation of IRF3, whereas the activation of the
NF-kB and MAPK pathways is slightly delayed and less
prominent compared to TLR signalling. This observation is
also reflected by the cytokine profile, as CMA induces high
levels of IFNb as opposed to IL-6. Studies using knockout
cells revealed that CMA triggers antiviral immunity cells
through the STING–TBK1–IRF3 route, which could be further
corroborated by gain-of-function experiments in cells devoid
of functional mmSTING.
Unexpectedly, human cells showed complete unrespon-
siveness towards CMA, although c-diGMP-dependent STING
activity was observed. We could ascribe this to species-
dependent differences within the C-terminal LBD of STING,
as HEK 293T cells expressing a chimeric STING protein
equipped with the murine LBD readily responded towards
CMA. Further studies could pinpoint the failure of human
STING to respond to CMA, to the inability of the human LBD
to form a stable complex. Of note, these experiments do not
formally proof that human STING cannot bind to CMA, yet in
light of the functional data this appears to be the most likely
scenario. The species-specific activation of murine STING by
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CMA activates STING
T Cavlar et al
1444 The EMBO Journal VOL 32 | NO 10 | 2013 &2013 European Molecular Biology Organization
CMA is surprising, especially given the fact that several
reports on antiviral activity in the human system both
in vitro and in vivo exist (Vershinina et al, 2002; Zarubaev
et al, 2003). One possibility is that these antiviral activities
are due to direct inhibition of viral replication, independent
of the innate immune response (e.g., inhibition of viral
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Figure 4 Species-specificity CMA activity is determined by the C-terminal LBD of STING. (A–D) 293T cells were transiently transfected with
the indicated STING constructs (25, 12.5, 6.25 and 0 ng), whereas 12.5 ng of pIFNa-GLuc reporter plasmid were included. For titrations, an
empty pCI vector served as a stuffer to obtain 200 ng total plasmid DNA. After 24 h, cells were transfected with c-diGMP or stimulated with
CMA (500 and 125 mg/ml). Luciferase activity was measured after an additional period of 24 h in the supernatant, and data were normalized
to the condition without STING overexpression. Plasmids coding for full-length hSTING (A), mmSTING (B), mmSTING(1-137)-hSTING(139-
379) (C) and hSTING(1-138)-mmSTING(138-378) (D) were tested. (E) Expression of the above described constructs was studied in 293T cells
24 h after transfection (200 ng per 96-well plate) using western blot, whereas b-actin served as a loading control. Representative results out of
three independent experiments are depicted. Source data for this figure is available on the online supplementary information page.
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polymerases). At the same time, it is conceivable that higher
local concentrations of CMA can be achieved during systemic
application or that other cell types are activated, both leading
to a STING-dependent type I IFN response. Nevertheless,
our results clearly question a predominant role for type I
IFN induction by CMA in the human system.
FAA (flavone-8-acetic acid) and DMXAA (5,6-dimethyl-9-
oxo-9H-xanthen-4-yl)-acetic acid) are two additional tricyclic
small-molecule compounds that have been reported to trigger
potent type I IFN responses in the murine system (Hornung
et al, 1988; Futami et al, 1991; Perera et al, 1994; Roberts
et al, 2007). Both compounds have been pursued for their
potent antitumour activity in murine tumour models, and for
both compounds it was shown that activation of the immune
system plays a pivotal role in therapeutic activity (Ching and
Baguley, 1987; Hornung et al, 1988; Pang et al, 1998). FAA,
however, failed to induce type I IFN responses in human
cells (Futami et al, 1991) and, moreover, it failed to
display antitumour activity in clinical trials (Bibby and
Double, 1993). In parallel, despite strong activity in the
murine system, DMXAA by itself also showed limited
immunostimulatory capacity in human cells (Patel et al,
1997; Philpott et al, 2001; Gobbi et al, 2006). At the same
time, DMXAA in combination with a platinum-based
chemotherapy did not show any efficacy in a large phase III
clinical trial for the treatment of non-small cell lung cancer
(Lara et al, 2011). Most recently, it has been reported that
DMXAA triggers type I IFN responses in a STING-dependent
fashion (Brunette et al, 2012; Prantner et al, 2012). In these
reports, only murine cells were tested and direct binding of
DMXAA to STING was not assessed. Nevertheless, given
the similarity of CMA and DMXAA at the molecular level,
we would expect that DMXAA also directly engages STING in
a species-specific manner. As such, it appears likely that the
failure of DMXAA in the human system can be attributed
to its inability to trigger STING activation.
At the structural level, the species-specific recognition of
CMA is unlikely to be attributable to the binding pocket itself.
This region, which is mainly formed by a-helices, a1 and a3,
is more or less invariant between the human and the murine
system, with all direct interactors of CMA being identical.
It is possible that more subtle structural differences prevent
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Figure 5 DSF implicates direct binding of CMA to murine, but not to human STING. (A,B) The interaction of STING with c-diGMP, c-diAMP
and CMA were analysed by thermal shift assay. Purified murine STING (A) and human STING (B) were tested with different concentrations
of c-diGMP/c-diAMP/CMA; (i) Schematic views of the protein domains used for binding studies are shown; (ii) thermal shifts of (iii)
fluorescence intensity versus temperature are shown. Representative results out of two independent experiments are depicted for the
temperature curves (ii), whereas mean valuesþ s.e.m. out of two independent experiments are depicted for the thermal shift graphs (iii).
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binding of CMA to human STING. An alternative, probably
more likely, explanation concerns loops b2 and b3 of the
LBD, which are critically involved in the coordination of
c-diGMP. While flexible in the apo form of human STING,
this loop region undergoes a conformational rearrangement
upon c-diGMP binding, thereby functioning as a ‘lid’ that
keeps c-diGMP within the binding pocket (Huang et al, 2012).
Two conserved residues within the tip of this loop (human:
Arg238, Tyr240) have been shown to interact with c-diGMP,
and point mutagenesis data support the critical role of the
loop region in c-diGMP recognition. In support of a similar
activation mechanism, CMA binds Arg237 of murine STING.
Interestingly, the previously reported R231A mutation within
this loop region impairs c-diGMP-mediated IFN induction
even though DNA- and CMA-dependent IFN induction are
not affected (Burdette et al, 2011). These data suggest that
the loop region is differently involved in CMA sensing,
as opposed to c-diGMP recognition. Consistent with the
mutational data, Arg231 is not involved in recognition of
CMA, and the tip of the lid, where this conserved residue is
located, is folded differently compared to the human STING
bound to c-diGMP (Figure 6C). As such, species-dependent
differences that may stabilize or allow this altered conforma-
tion could account for the observed unresponsiveness
of hSTING towards CMA. Yet, additional studies will be
required to pinpoint this phenomenon to an exact structural
determinant.
This is the first report of a direct STING ligand that is not a
cyclic dinucleotide. Most intriguingly, CMA is not sensed
as a monomeric ligand within the ligand-binding pocket of
the STING dimer; yet, two molecules positioned in a
rotational symmetry are required to activate STING. We
assume that other reported tricyclic small-molecule antivirals
(e.g., tilorone, DMXAA, etc) are also sensed as a dimeric
ligand in a fashion similar to CMA. Moreover, it is tempting to
speculate that beyond these synthetic compounds, natural
ligands exist that also follow a CMA-like recognition mode.
In this regard, several bioflavonoids reported to exert
antiviral activity might be interesting candidates. At the
same time, the novel class of STING ligands described here
might open novel avenues to develop compounds that block
STING activation, with favorable drug-like properties. Given
the likely involvement of STING in sensing endogenous DNA
in the course of sterile inflammatory conditions (Ahn et al,
2012; Gall et al, 2012), pharmacological targeting of STING
might constitute a reasonable therapeutic venture.
Materials and methods
Reagents
Poly(I:C) and CMA were purchased from Sigma Aldrich. Ultra-pure
LPS from E. coli was purchased from Invivogen. c-diGMP and
c-diAMP were from BioLog. GeneJuice Transfection Reagent was
from Novagen. Lipofectamine 2000 was from Life Technologies.
Goat anti-rabbit-IgG-HRP, goat-anti-mouse-IgG-HRP and anti-
b-actin-IgG-HRP were from Santa Cruz Biotechnology. Passive
lysis buffer was purchased from Promega.
Plasmids
Expression plasmids coding for human or murine STING were
cloned into pEFBOS coding for an N-terminal GFP or an N-terminal
mCherry tag. Chimeric STING constructs, human STING (AA1–
B
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Figure 6 Structural basis for CMA recognition. (A) Ribbon model of the mouse STING dimer (light and dark brown) with highlighted
secondary structure. The two bound CMA molecules are shown as magenta stick models. (B) Close-up view of the CMA-binding site with
superimposed 2mFo-DFc electron density (blue; contoured at 1.4). One STING protomer is shown in light brown. For the other protomer
(brown), only the lid is displayed. Folding of the lid via hydrogen bonds to Arg237 and Tyr239 suggests how CMA activates mouse STING.
(C,D) Side-by-side comparison of CMA bound to mouse STING (C) and c-diGMP bound to human STING (D) showing selected interactions.
CMA folds the lid differently from c-diGMP, due to steric clash with Arg231 (human Arg232), which binds c-diGMP via a magnesium ion/water
molecule.
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138)–murine STING (AA138–378) and murine STING (AA1–137)–
human STING (AA139–379) were generated by ligation-indepen-
dent cloning (Aslanidis and de Jong, 1990; Schmid-Burgk et al,
2012). The STING mutants (I199N, R231A in pEFBOS-mCherry)
were generated by point mutagenesis PCR. pCI-empty was used as a
stuffer. All primer sequences used for cloning are available upon
request.
Cell culture
PBMCs were isolated from whole blood of healthy donors. After
Ficoll density-gradient centrifugation (Biochrom), red blood cells
were lysed using lysing buffer (BD Biosciences). PBMCs were
seeded with a density of 4106 per ml at 100ml in a 96-well plate
containing RPMI supplemented with 10% (v/v) FCS, sodium pyr-
uvate, penicillin and streptomycin (all from Life Technologies).
293T and primary human fibroblasts were cultured in DMEM
supplemented with 10% (v/v) FCS, sodium pyruvate (all from
Life technologies) and Ciprofloxacin (Bayer Schering Pharma).
Primary macrophages were generated from mouse bone marrow
cells that were cultured for 7 days in DMEM with the same additives
as described above and 30% (v/v) L929 supernatant.
Immunoblotting
Primary macrophages were lysed in 1 Laemmli buffer and
denatured at 951C for 5 min. Probes were separated by 10% SDS–
PAGE and transferred onto nitrocellulose membranes. Blots were
incubated with anti-Phospho-IRF3 (number 4947), anti-Phospho-
NF-kappaB-p65 (number 3033), anti-Phospho-p38 (number 4511),
anti-IkappaB-alpha (number 4814) or anti-Phospho-SAPK/JNK
(number 9255) from Cell Signaling Technology.
Transfection
For transfection experiments, primary macrophages were seeded
with a density of 1105 per ml. Cells were transfected with poly
(I:C) (2mg/ml), pppRNA (1.33mg/ml), ISD (2mg/ml) and c-diGMP
(8.66mg/ml) using Lipofectamine 2000 (Life Technologies), accord-
ing to the manufacturer’s instructions. LPS (200 ng/ml) and CMA
were directly added to the medium. Human PBMCs were trans-
fected as described above, at a density of 4106 per ml, human
fibroblasts at a density of 1.5105 per ml. For western blot experi-
ments, cells were lysed after 2 h, if not indicated otherwise. For
cytokine assays, supernatants were collected after 18–20 h. For RNA
isolation, cells were lysed after 4 h.
Enzyme-linked immunosorbent assay
Cell culture supernatants were assayed for human IP-10 (BD
Biosciences), human IL-6 (BD Biosciences), human IFNa
(eBioscience), mouse IFNb (BioLegend), mouse IP-10 (R&D
Systems) or mouse IL-6 (BD Biosciences), according to the manu-
facturer’s instructions.
Quantitative real-time PCR analysis
RNA from macrophages was reverse transcribed using the
RevertAid First Strand cDNA Synthesis kit (Fermentas) and quanti-
tative PCR analysis was performed on an ABI 7900HT. All murine
gene expression data are presented as relative expression to HPRT1.
Primer sequences are available upon request.
Luminescence assays
pIFNb-FFLuc macrophages (Lienenklaus et al, 2009) were
stimulated as indicated and were lysed with passive lysis
buffer 18–20 h after stimulation, to determine luminescence. For
VSV*DG(Luc) replicon assays, macrophages were treated with
ligands or supernatants as indicated and subsequently infected at
an MOI of 10 with the VSV*DG(Luc) replicon virus particles. Firefly-
luciferase activity was measured in the lysates using a 2104
EnVision Multilabel reader from Perkin-Elmer.
Plasmid overexpression experiments
293Tcells were seeded with a density of 2105 cells per ml at 100ml
96-well plate. IFNb (12.5 ng) promoter–reporter plasmid pIFNb–
GLuc or pELAM-GLuc, and STING constructs were transfected using
GeneJuice according to the manufacturer’s instructions. For
titration experiments, empty pCI vector was used as a stuffer.
After 24 h, the cells were transfected with c-diGMP or were stimu-
lated with CMA. After further 20 h, GLuc activity was measured in
the supernatants using coelenterazine as a substrate.
Cell viability assays
Cell viability was assessed using CellTiter-Blue (Promega)
according to the manufacturer’s instructions. The assay was per-
formed immediately after (Gaussia) or before (Firefly) luciferase
measurement.
Differential scanning fluorimetry
Thermal shift assays were carried out using a CFX 96TM Real-Time
System (Biorad) for recording the fluorescence signal (HEX: Ex/Em:
450–490/560–580 nm) as a function of temperature. The tempera-
ture gradient was set from 15 to 801C, with an increment of 0.51C
and incubation steps of 15 s. Each 20 ml reaction (buffer: 20 mM
Tris, 150 mM NaCl, (10% DMSO for reactions with CMA), pH 7.5),
with or without 2 mM/1 mM/0.5 mM of c-diGMP/c-diAMP/CMA
contained 1 mg/ml of STING and a dilution of 1:500 of SYPRO
Orange dye (Invitrogen).
Cloning of human and mouse STING constructs for protein
expression
Human STING AA139–379 (R220HþH232R) was cloned from a
human macrophage cDNA library into pET28-SUMO1-eGFP vector
via BamHI and NotI restriction sites. The mouse STING constructs
AA138–378 and AA138–341 were cloned from a mouse lung tissue
cDNA library into pET28-SUMO1-eGFP vector via AgeI and NotI
restriction sites. These plasmids were used to transform
E. coli Rosetta (DE3) protein expression strain cells (Novagen).
Expression and purification of human and mouse STING
constructs
For all used STING constructs, the expression and purification
procedure was the following: E. coli Rosetta (DE3) cells were
grown in 3 l of LB media supplemented with Kanamycin (50 mg/l)
and Chloramphenicol (34 mg/l) at 371C for 3 h, to OD600¼ 0.8.
Expression of N-terminal His6-SUMO1-tagged STING was induced
by adding IPTG (Roth) to a final concentration of 0.2 mM.
Expression was done overnight at 181C. Cells were collected by
centrifugation and were resuspended in lysis buffer (50 mM Tris,
500 mM NaCl, 10 mM imidazole, 5% glycerol, 2 mM b-mercap-
toethanol, pH 7.5) and lysed by sonication. The soluble His6-
SUMO1-STING was purified by Ni-affinity chromatography.
The His6-SUMO1-tag was removed by proteolytic cleavage with
SenP2 protease during dialysis overnight (20 mM Tris, 150 mM
NaCl, 3% glycerol, 2 mM b-mercaptoethanol, pH 7.5) and a second
Ni-affinity chromatography step. To remove additional contami-
nants, a HiTrap Q FF (GE Healthcare) purification was applied.
Finally, the STING containing flow-through was used in a HiLoadTM
26/60 Superdex 75 prep grade (GE Healthcare) size-exclusion
chromatography step (20 mM Tris, 150 mM NaCl, pH 7.5).
Purified STING was concentrated (10–15 mg/ml) with a 10 kDa
cut-off centrifugal concentrator device (Millipore) and was flash
frozen in liquid nitrogen for storage ( 801C).
Crystallization of mmSTING AA149–348 with CMA
A protein solution of mmSTING (8 mg/ml) was saturated with CMA
(by adding solid powder due to its low solubility in aqueous
solution) and incubated on ice for 1 h. Prior to crystallization,
the protein solution was centrifugated and filtered to remove solid
CMA. Crystals were grown using the hanging drop vapour diffusion
method with drops of 1:1 ratio protein:reservoir. The reservoir
solution contained 0.1 M HEPES, pH 7, 1.65 M ammonium sulphate,
2% PEG 400 (v/v) and saturating amounts of CMA. mmSTING
crystals appeared after B4 days at 201C. For cryoprotection, the
crystals were soaked in reservoir solution containing 12% (±)-1,3-
butanediol (v/v) before flash freezing in liquid nitrogen.
Data collection and structure determination
X-ray diffraction data were collected at beamline X06SA at the
Swiss Light Source (Villigen, Switzerland). Data processing was
carried out using XDS (Kabsch, 2010). The structure was solved by
molecular replacement with PHASER (McCoy et al, 2007) from the
ccp4 package (Winn et al, 2011), using a mouse search model
created from the human STING structure (4EMT (Shu et al,
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2012)) by ClustalW2 alignment (Goujon et al, 2010; Larkin et al,
2007) and modelling with the SWISS-MODEL structure homology-
modelling server (Peitsch, 1995; Arnold et al, 2006; Kiefer et al,
2009). The structure was refined by rounds of manual model
building carried out with COOT (Emsley and Cowtan, 2004) and
refinement using Phenix (Adams et al, 2010). The final structure
with R/Rfree¼ 21/23.7 shows good stereochemistry and no outliers
in the Ramachandran plot. Figures were created with PyMOL
(Schro¨dinger, 2010). Coordinates and structure factors have been
deposited with the Protein Data Bank (accession number 4JC5).
Supplementary Data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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